Pharma company Visiblegy will increase its headcount to help it meet new growth targets.
Visiblegy, a start-up working in the global pharmaceutical space, is set to hire 11 new staff as part of a new investment strategy. The jobs, two of which are already in place, cover a range of positions, including software programming, marketing, sales and managerial roles.
These positions will be recruited in the Fermanagh and Omagh areas throughout 2019. The hires are being supported by Invest NI, with funding going towards both this recruitment drive and market developments, which will enable the firm to increase its market presence and reach growth targets.
Visiblegy’s software platform, XLens, delivers insights that support the launch of new drugs into the marketplace.
“XLens is aimed at eliminating the billions of dollars of revenue leakage that the pharma industry experiences when new products are launched on to the marketplace,” explained Mark Bradley, director at Visiblegy, as he celebrated the jobs announcement. “We have received encouraging feedback from customers to date and are aiming to generate further sales over the coming months.”
Also welcoming the news was Ethna McNamee, western regional manager at Invest NI, who said: “Visiblegy is an impressive young business with high growth potential. The significant export contract secured in its first year of trading is a valuable endorsement of the importance of its technology to the global pharmaceutical industry.
“[This] is very positive news for the Fermanagh and Omagh District Council area. We are committed to helping this business achieve its targets and maximise the global opportunities which exist for its innovative technology.”
This latest development continues the success Northern Ireland profited from in 2018 on the job front, with more jobs created in Ulster in 2018 than in 2017. Though it is still to be determined, this could have something to do with Brexit, which IDA Ireland reported has created 4,500 jobs in Ireland this year. Brexit fears are particularly relevant to the pharmaceutical industry, which will unquestionably be impacted intensely by Britain exiting the single market, though whether it will be in a positive or negative way remains to be seen.
